Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited announced that its drug afamelanotide has been granted an orphan drug designation by the European Medicines Agency for treating xeroderma pigmentosum, a condition with no current treatments. The designation, which is the fifth of its kind for afamelanotide, offers financial and regulatory incentives, including reduced fees and ten years of market exclusivity post-approval. This milestone recognizes the drug’s potential to reduce UV skin damage and enhance DNA repair in patients with this rare genetic disorder.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
